Personalized approach to the management of patients with cardiovascular diseases in outpatient practice (literature review)

Cover Page

Cite item

Full Text

Abstract

The article discusses the key aspects of a personalized approach to the management of patients with cardiovascular diseases at the outpatient stage. Personalized medicine based on a deep understanding of the individual characteristics of the patient makes it possible to optimize strategies for the prevention and treatment of cardiovascular diseases. The review highlights the issues of stratification of individual cardiovascular risk using validated scales and imaging methods, the selection of targets for blood pressure, lipids and blood glucose, taking into account the clinical profile of the patient. The importance of selecting the optimal drug therapy based on concomitant diseases, potential drug interactions, predictors of efficacy and safety is emphasized. Approaches to increasing patient adherence, control of tolerability of therapy and drug interactions are considered. The role of patient-oriented counseling, patient involvement in the decision-making process and training programs is discussed. The importance of continuity of patient management, multidisciplinary interaction of cardiologists, primary care physicians and specialists is highlighted. It is con-cluded that the introduction of the principles of personalized medicine into outpatient prac-tice opens the way to more effective, safe and patient-oriented care for patients with cardiovascular diseases.

About the authors

Ibragim M. Khapokhov

Russian Medical Academy of Life-long Professional Learning; Clinical and Diagnostic Center No. 4 of Moscow Department of Health

Email: Ibragim.xapohov@gmail.com

Lecturer of the sub-department of general medical practice and outpatient therapy; local general practitioner

(building 1, 2/1 Barrikadnaya street, Moscow, Russia); (3 Krylatskiye kholmy, Moscow, Russia)

Aleksey S. Ryazanov

Russian Medical Academy of Life-long Professional Learning

Author for correspondence.
Email: alexeydoc72@yandex.ru

Doctor of medical sciences, professor, head of the sub-department of general medical practice and outpatient therapy

(building 1, 2/1 Barrikadnaya street, Moscow, Russia)

References

  1. Roth G.A., Johnson C., Abajobir A. et al. Global, Regional, and National Burden of Car-diovascular Diseases for 10 Causes, 1990 to 2015. J Am Coll Cardiol. 2017;70(1):1‒25.
  2. Federal'naya sluzhba gosudarstvennoy statistiki. Estestvennoe dvizhenie naseleniya v razreze sub"ektov Rossiyskoy Federatsii za 2019 god = Federal State Statistics Service. Natural population movement by subjects of the Russian Federation for 2019. (In Russ.). Available at: https://rosstat.gov.ru/
  3. Karpov Yu.A., Kukharchuk V.V., Lyakishev A.A. et al. Diagnostics and correction of lipid metabolism disorders for the prevention and treatment of atherosclerosis. Ateroskleroz i dislipidemii = Atherosclerosis and dyslipidemia. 2017;3(28):5‒(In Russ.)
  4. Chazova I.E., Zhernakova Yu.V. On behalf of the experts. Clinical guidelines. Diagno-sis and treatment of arterial hypertension. Sistemnye gipertenzii = Systemic hyperten-sion. 2019;16(1):6‒31. (In Russ.)
  5. Kotseva K., De Backer G., De Bacquer D. et al. Primary prevention efforts are poorly developed in people at high cardiovascular risk: A report from the European Society of Cardiology EURObservational Research Programme EUROASPIRE V survey in 16 Eu-ropean countries. Eur J Prev Cardiol. 2021;28(4):370–379.
  6. Schulman-Marcus J., Rubenfire M. Precision Medicine in Lipid Management and Athero-sclerotic Cardiovascular Disease Prevention. Curr Cardiol Rep. 2021;23(2):13.
  7. Redfors B., Chen S., Crowley A. et al. Personalised Antiplatelet Therapy Following PCI: A Meta-Analysis of Randomised Controlled Trials. Heart. 2017;103(19):1498–1506.
  8. Eindhoven D.C., Hilt A.D., Zwaan T.C., Schalij M.J., Borleffs C.J.W. Age and gender differences in medical adherence after myocardial infarction: Women do not receive optimal treatment ‒ The Netherlands claims database. Eur J Prev Cardiol. 2018;25(2):181‒189.
  9. Kirchhof P., Benussi S., Kotecha D. et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893‒2962.
  10. McManus D.D., Saczynski J.S., Lessard D. et al. Recent Trends in the Incidence, Treat-ment, and Prognosis of Patients with Heart Failure and Atrial Fibrillation (the Worcester Heart Failure Study). Am J Cardiol. 2013;111(10):1460–1465.
  11. Piepoli M.F., Hoes A.W., Agewall S. et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European So-ciety of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clini-cal Practice. Eur Heart J. 2016;37(29):2315‒2381.
  12. Visseren F.L.J., Mach F., Smulders Y.M. et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227‒3337.
  13. Assmann G., Cullen P., Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Münster (PROCAM) study. Circulation. 2002;105(3):310‒315.
  14. Hippisley-Cox J., Coupland C., Brindle P. Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective co-hort study. BMJ. 2017;357:j2099.
  15. Knuuti J., Wijns W., Saraste A. et al. 2019 ESC Guidelines for the diagnosis and man-agement of chronic coronary syndromes. Eur Heart J. 2020;41(3):407‒477.
  16. Fox K.A.A., Metra M., Morais J., Atar D. The myth of 'stable' coronary artery disease. Nat Rev Cardiol. 2020;17(1):9‒21.
  17. Granger C.B., Goldberg R.J., Dabbous O. et al. Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med. 2003;163(19):2345‒2353.
  18. Williams B., Mancia G., Spiering W. et al. 2018 ESC/ESH Guidelines for the manage-ment of arterial hypertension. Eur Heart J. 2018;39(33):3021‒3104.
  19. Mach F., Baigent C., Catapano A.L. et al. 2019 ESC/EAS Guidelines for the manage-ment of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111‒188.
  20. Cosentino F., Grant P.J., Aboyans V. et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255‒323.
  21. Madhavan M.V., Gersh B.J., Alexander K.P., Granger C.B., Stone G.W. Coronary Ar-tery Disease in Patients ≥80 Years of Age. J Am Coll Cardiol. 2018;71(18):2015‒2040.
  22. Benetos A., Bulpitt C.J., Petrovic M. et al. An Expert Opinion From the European Soci-ety of Hypertension-European Union Geriatric Medicine Society Working Group on the Management of Hypertension in Very Old, Frail Subjects. Hypertension. 2016;67(5):820‒825.
  23. Stacey D., Légaré F., Lewis K. et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev. 2017;4(4):CD001431.
  24. Olechowski B., Ashby A., Mariathas M. et al. Optimisation of pharmacotherapy in old-er patients with cardiovascular disease. J Geriatr Cardiol. 2020;17(7):388‒402.
  25. Ruiz-Iruela C., Padullés-Zamora N., Pintó-Sala X. Pharmacogenetic biomarkers of car-dio-vascular diseases. Biochem Pharmacol. 2021;114697.
  26. Messerli F.H., Bangalore S., Bavishi C., Rimoldi S.F. Angiotensin-Converting Enzyme Inhibitors in Hypertension: To Use or Not to Use? J Am Coll Cardiol. 2018;71(13):1474‒1482.
  27. Khatib R., Patel N., Laverty U. et al. ACE inhibitors/ARBs for patients with cardiovas-cular disease without heart failure: a review of the evidence from randomized con-trolled trials. J Hypertens. 2021;39(1):18‒27.
  28. Ponikowski P., Voors A.A., Anker S.D. et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(27):2129‒2200.
  29. Schwalm J.D., McKee M., Huffman M.D., Yusuf S. Resource Effective Strategies to Prevent and Treat Cardiovascular Disease. Circulation. 2016;133(8):742‒755.
  30. Poole-Wilson P.A., Swedberg K., Cleland J.G. et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet. 2003;362(9377):7‒13.
  31. Giugliano R.P., Cannon C.P., Blazing M.A. et al. Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With vs Without Di-abetes: Results From IMPROVE-IT. Circulation. 2018;137(15):1571‒1582.
  32. Neumann F.J., Sousa-Uva M., Ahlsson A. et al. 2018 ESC/EACTS Guidelines on myo-cardial revascularization. Eur Heart J. 2019;40(2):87‒165.
  33. Valgimigli M., Bueno H., Byrne R.A. et al. 2017 ESC focused update on dual antiplate-let therapy in coronary artery disease developed in collaboration with EACTS. Eur J Cardio-thorac Surg. 2018;53(1):34‒78.
  34. Mosca L., Barrett-Connor E., Wenger N.K. Sex/gender differences in cardiovascular disease prevention: what a difference a decade makes. Circulation. 2011;124(19):2145‒2154.
  35. Hindricks G., Potpara T., Dagres N. et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373‒498.
  36. Ruff C.T., Giugliano R.P., Braunwald E. et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955‒962.
  37. Lip G.Y.H., Collet J.P., Haude M. et al. 2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interven-tions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA). Europace. 2019;21(2):192‒193.
  38. Cosentino F., Ceriello A., Baeres F.M.M. et al. Addressing cardiovascular risk in type 2 diabetes mellitus: a report from the European Society of Cardiology Cardiovascular Roundtable. Eur Heart J. 2019;40(34):2907‒2919.
  39. Marso S.P., Daniels G.H., Brown-Frandsen K. et al. Liraglutide and Cardiovascular Out-comes in Type 2 Diabetes. N Engl J Med. 2016;375(4):311‒322.
  40. Verma S., McMurray J.J.V. SGLT2 inhibitors and mechanisms of cardiovascular bene-fit: a state-of-the-art review. Diabetologia. 2018;61(10):2108‒2117.
  41. Zelniker T.A., Wiviott S.D., Raz I. et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic re-view and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393(10166):31‒39.
  42. Sabate E. Adherence to long-term therapies: evidence for action. World Health Organi-zation. 2003;2(4):323.
  43. Morisky D.E., Green L.W., Levine D.M. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24(1):67‒74.
  44. Kronish I.M., Ye S. Adherence to cardiovascular medications: lessons learned and fu-ture directions. Prog Cardiovasc Dis. 2013;55(6):590‒600.
  45. Gupta P., Patel P., Strauch B. et al. Risk Factors for Nonadherence to Antihypertensive Treatment. Hypertension. 2017;69(6):1113‒1120.
  46. Conn V.S., Ruppar T.M., Chan K.C., Dunbar-Jacob J., Pepper G.A., De Geest S. Pack-aging interventions to increase medication adherence: systematic review and meta-analysis. Curr Med Res Opin. 2015;31(1):145‒160.
  47. Kronish I.M., Woodward M., Sergie Z., Ogedegbe G., Falzon L., Mann D.M. Meta-analysis: impact of drug class on adherence to antihypertensives. Circulation. 2011;123(15):1611‒1621.
  48. Steinman M.A., Hanlon J.T. Managing medications in clinically complex elders: "There's got to be a happy medium". JAMA. 2010;304(14):1592‒601.
  49. Benson J. , Britten N. Patients' decisions about whether or not to take antihypertensive drugs: qualitative study. BMJ. 2002;325(7369):873.
  50. Formica D., Sultana J., Cutroneo P.M. et al. The economic burden of preventable ad-verse drug reactions: a systematic review of observational studies. Expert Opin Drug Saf. 2018;17(7):681‒695.
  51. Hargraves I., LeBlanc A., Shah N.D., Montori V.M. Shared Decision Making: The Need For Patient-Clinician Conversation, Not Just Information. Health Aff (Millwood). 2016;35(4):627‒629.
  52. Whitehead L., Seaton P. The Effectiveness of Self-Management Mobile Phone and Tablet Apps in Long-term Condition Management: A Systematic Review. J Med Internet Res. 2016;18(5):e97.
  53. Kitsiou S., Paré G., Jaana M. Effects of home telemonitoring interventions on patients with chronic heart failure: an overview of systematic reviews. J Med Internet Res. 2015;17(3):e63.
  54. Thakkar J., Kurup R., Laba T.L. et al. Mobile Telephone Text Messaging for Medica-tion Adherence in Chronic Disease: A Meta-analysis. JAMA Intern Med. 2016;176(3):340‒349.
  55. Smith S.M., Soubhi H., Fortin M., Hudon C., O'Dowd T. Managing patients with multimor-bidity: systematic review of interventions in primary care and community settings. BMJ. 2012;345:e5205.
  56. Jernberg T., Hasvold P., Henriksson M., Hjelm H., Thuresson M., Janzon M. Cardio-vascular risk in post-myocardial infarction patients: nationwide real world data demon-strate the importance of a long-term perspective. Eur Heart J. 2015;36(19):1163‒1170.
  57. Kotseva K., Wood D., De Bacquer D. et al. EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. Eur J Prev Cardiol. 2016;23(6):636‒648.
  58. Jorstad H.T., von Birgelen C., Alings A.M. et al. Effect of a nurse-coordinated preven-tion programme on cardiovascular risk after an acute coronary syndrome: main results of the RESPONSE randomised trial. Heart. 2013;99(19):1421‒1430.
  59. Cleland J.G., Louis A.A., Rigby A.S., Janssens U., Balk A.H.; TEN-HMS Investigators. Noninvasive home telemonitoring for patients with heart failure at high risk of recurrent admission and death: the Trans-European Network-Home-Care Management System (TEN-HMS) study. J Am Coll Cardiol. 2005;45(10):1654‒1664.
  60. Van Spall H.G.C., Rahman T., Mytton O. et al. Comparative effectiveness of transi-tional care services in patients discharged from the hospital with heart failure: a system-atic review and network meta-analysis. Eur J Heart Fail. 2017;19(11):1427‒1443.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Согласие на обработку персональных данных с помощью сервиса «Яндекс.Метрика»

1. Я (далее – «Пользователь» или «Субъект персональных данных»), осуществляя использование сайта https://journals.rcsi.science/ (далее – «Сайт»), подтверждая свою полную дееспособность даю согласие на обработку персональных данных с использованием средств автоматизации Оператору - федеральному государственному бюджетному учреждению «Российский центр научной информации» (РЦНИ), далее – «Оператор», расположенному по адресу: 119991, г. Москва, Ленинский просп., д.32А, со следующими условиями.

2. Категории обрабатываемых данных: файлы «cookies» (куки-файлы). Файлы «cookie» – это небольшой текстовый файл, который веб-сервер может хранить в браузере Пользователя. Данные файлы веб-сервер загружает на устройство Пользователя при посещении им Сайта. При каждом следующем посещении Пользователем Сайта «cookie» файлы отправляются на Сайт Оператора. Данные файлы позволяют Сайту распознавать устройство Пользователя. Содержимое такого файла может как относиться, так и не относиться к персональным данным, в зависимости от того, содержит ли такой файл персональные данные или содержит обезличенные технические данные.

3. Цель обработки персональных данных: анализ пользовательской активности с помощью сервиса «Яндекс.Метрика».

4. Категории субъектов персональных данных: все Пользователи Сайта, которые дали согласие на обработку файлов «cookie».

5. Способы обработки: сбор, запись, систематизация, накопление, хранение, уточнение (обновление, изменение), извлечение, использование, передача (доступ, предоставление), блокирование, удаление, уничтожение персональных данных.

6. Срок обработки и хранения: до получения от Субъекта персональных данных требования о прекращении обработки/отзыва согласия.

7. Способ отзыва: заявление об отзыве в письменном виде путём его направления на адрес электронной почты Оператора: info@rcsi.science или путем письменного обращения по юридическому адресу: 119991, г. Москва, Ленинский просп., д.32А

8. Субъект персональных данных вправе запретить своему оборудованию прием этих данных или ограничить прием этих данных. При отказе от получения таких данных или при ограничении приема данных некоторые функции Сайта могут работать некорректно. Субъект персональных данных обязуется сам настроить свое оборудование таким способом, чтобы оно обеспечивало адекватный его желаниям режим работы и уровень защиты данных файлов «cookie», Оператор не предоставляет технологических и правовых консультаций на темы подобного характера.

9. Порядок уничтожения персональных данных при достижении цели их обработки или при наступлении иных законных оснований определяется Оператором в соответствии с законодательством Российской Федерации.

10. Я согласен/согласна квалифицировать в качестве своей простой электронной подписи под настоящим Согласием и под Политикой обработки персональных данных выполнение мною следующего действия на сайте: https://journals.rcsi.science/ нажатие мною на интерфейсе с текстом: «Сайт использует сервис «Яндекс.Метрика» (который использует файлы «cookie») на элемент с текстом «Принять и продолжить».